Kamada (KMDA) Non-Current Deffered Revenue (2016 - 2021)
Kamada (KMDA) posted quarterly Non-Current Deffered Revenue of $15000.0 for Q4 2021, down 99.26% year-on-year from $2.0 million in Q4 2020, and down 99.26% on a QoQ basis from $2.0 million in Q4 2020.
Kamada (KMDA) Non-Current Deffered Revenue (2016 - 2021) Analysis & Trends
Kamada (KMDA) has reported Non-Current Deffered Revenue for 6 consecutive years, with $15000.0 the latest figure, recorded in Q4 2021.
- Quarterly Non-Current Deffered Revenue fell 99.26% year-over-year to $15000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $15000.0 (down 99.26% YoY) and the FY2021 annual result came in at $15000.0, down 99.26% from the prior year.
- Non-Current Deffered Revenue fell to $15000.0 in Q4 2021 per KMDA's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for KMDA reached as high as $2.0 million in Q4 2020 and fell as low as $15000.0 in Q4 2021.
- A 5-year average of $729400.0 and a median of $668000.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue surged 772.84% — and 2021, when it sank 99.26%.
- Year by year, Non-Current Deffered Revenue stood at $707000.0 in 2017, then slipped by 5.52% to $668000.0 in 2018, then slumped by 65.27% to $232000.0 in 2019, then jumped by 772.84% to $2.0 million in 2020, then plunged by 99.26% to $15000.0 in 2021.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $15000.0, $2.0 million, and $232000.0 for Q4 2021, Q4 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 15,000.00 |
| Dec 31, 2020 | 2.03 Mn |
| Dec 31, 2019 | 232,000.00 |
| Dec 31, 2018 | 668,000.00 |
| Dec 31, 2017 | 707,000.00 |
| Dec 31, 2016 | 3.66 Mn |